Myocardial Homing of Mesenchyme Stem Cells in Dilated Cardiomyopathy

Author(s): Delgado M J

Dilated cardiomyopathy (DCM) is the most common form of non-ischemic cardiomyopathy that leads to heart failure. Mesenchymal stem cells (MSCs) are under active disquisition presently as a eventuality remedy for DCM. Still, little information is available about the remedial eventuality of intravenous administration of MSCs for DCM. Also, how MSCs home to the myocardium in DCM is also unclear. DCM was convinced by intra peritoneal administering Doxorubicin and MSCs or vehicles were invested through the internal jugular tone. Cardiac functions including the chance of fractional shortening, left ventricular diastolic dimension, left ventricular end- diastolic pressure, and left ventricular maximum dp/ dt were estimated by echocardiographic and hemodynamic studies. Fibrosis was determined by Masson’s trichrome staining. The mRNA expression situations of monocyte chemotactic protein